Drug Target Review2024-04-16T12:30:17
The new findings could result in a clinical trial to assess whether a one-year course of treatment could stop brain tumours.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-06-29T06:49:00
Contributor Laura Alvarez, Drug Target Review
2026-06-15T07:00:00
Contributor Professor Dipak Ramji, Drug Target Review
2023-07-04T10:05:58
Sponsored by Revvity
2024-01-26T13:22:42
Sponsored by bit.bio
2026-06-04T07:05:00
Author Graham Craig
2023-12-11T10:49:07
Sponsored by Leica Microsystems
Site powered by Webvision Cloud